Prelude Therapeutics (PRLD) EBT Growth (3y) (2022 - 2026)

Prelude Therapeutics (PRLD) EBT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Prelude Therapeutics 324.30 Mn 179.71 Mn - 3.40%

Historic Data

Download Data
DateValue
Mar 31, 2026 3.40%
Dec 31, 2025 49.97%
Sep 30, 2025 0.38%
Jun 30, 2025 -13.59%
Mar 31, 2025 -11.44%
Dec 31, 2024 31.81%
Sep 30, 2024 23.40%
Jun 30, 2024 20.52%
Mar 31, 2024 32.66%
Dec 31, 2023 10.24%
Sep 30, 2023 40.62%
Jun 30, 2023 -48.96%
Mar 31, 2023 -57.74%
Dec 31, 2022 -78.25%
Sep 30, 2022 -83.46%